Physician profile
Daniel Steigman
NPI 1003840885
$907.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $254 · 2021: $266.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $383.85 | 2019-2021 | |
| Genzyme Corporation | $128.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $86.94 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $46.61 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $33.42 | 2020 | |
| Mylan Specialty L.P. | $24.00 | 2019 | |
| Grifols USA, LLC | $22.89 | 2019 | |
| Genentech USA, INC. | $20.95 | 2019 | |
| Merck Sharp & Dohme LLC | $20.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.83 | 2019 | |
| Covidien Lp | $17.23 | 2020 | |
| Pfizer INC. | $17.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Steigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.